ADA and Immunodeficiency: It was 30 years ago when the first gene therapy had started transfusing autologous T cells that were retrovirally transduced to produce adenosine deaminase (ADA) to two girls aged 4 and 9 years, respectively, with severe combined immunodeficiency due to ADA shortage (ADA-SCID) [1, 2].